BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Slater K, Hoo PS, Buckley AM, Piulats JM, Villanueva A, Portela A, Kennedy BN. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer Metastasis Rev 2018;37:335-45. [DOI: 10.1007/s10555-018-9751-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Slater K, Bosch R, Smith KF, Jahangir CA, Garcia-Mulero S, Rahman A, O'Connell F, Piulats JM, O'Neill V, Horgan N, Coupland SE, O'Sullivan J, Gallagher WM, Villanueva A, Kennedy BN. 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model. Front Med (Lausanne) 2022;9:1036322. [PMID: 36698840 DOI: 10.3389/fmed.2022.1036322] [Reference Citation Analysis]
2 Pyrak B, Rogacka K, Pisklak DM. Anti-leukotriene drugs in the therapy of inflammatory diseases. pps 2022;20:1-23. [DOI: 10.56782/pps.38] [Reference Citation Analysis]
3 Su K, Zheng X, Bréchot C, Zheng X, Zhu D, Huang R, Zhang Y, Tao J, Lou Y, Li L. Five-lipoxygenase-activating protein-mediated CYLD attenuation is a candidate driver in hepatic malignant lesion. Front Oncol 2022;12:912881. [DOI: 10.3389/fonc.2022.912881] [Reference Citation Analysis]
4 Lv X, Ding M, Liu Y. Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy. Front Immunol 2022;13:848455. [PMID: 35309331 DOI: 10.3389/fimmu.2022.848455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sundaramurthi H, García-mulero S, Tonelotto V, Slater K, Marcone S, Piulats JM, Watson RW, Tobin DJ, Jensen LD, Kennedy BN. Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. Cancers 2022;14:782. [DOI: 10.3390/cancers14030782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mahon N, Slater K, O'Brien J, Alvarez Y, Reynolds A, Kennedy B. Discovery and Development of the Quininib Series of Ocular Drugs. J Ocul Pharmacol Ther 2022;38:33-42. [PMID: 35089801 DOI: 10.1089/jop.2021.0074] [Reference Citation Analysis]
7 Kim YJ, Lee CS, Lee SC. Uveal Melanoma: A Review of the Literature and Personal Experiences. J Retin 2021;6:65-74. [DOI: 10.21561/jor.2021.6.2.65] [Reference Citation Analysis]
8 Sundaramurthi H, García-mulero S, Slater K, Marcone S, Piulats JM, Watson RW, Tobin DJ, Jensen LD, Kennedy BN. Inhibition of Metastatic Uveal Melanoma Cell Proliferation by the Histone Deacetylase 6 Inhibitor, Ricolinostat, is Linked to Altered Microphthalmia-associated Transcription Factor and Phospho-ERK Expression.. [DOI: 10.1101/2021.10.28.466226] [Reference Citation Analysis]
9 Akin-Bali DF. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma. Ophthalmic Genet 2021;:1-12. [PMID: 34353217 DOI: 10.1080/13816810.2021.1961280] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Nell RJ, Menger NV, Versluis M, Luyten GPM, Verdijk RM, Madigan MC, Jager MJ, van der Velden PA. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma. BMC Cancer 2021;21:164. [PMID: 33588787 DOI: 10.1186/s12885-021-07865-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
11 Saier L, Peyruchaud O. Emerging role of cysteinyl LTs in cancer. Br J Pharmacol 2021. [PMID: 33527344 DOI: 10.1111/bph.15402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Luo H, Ma C. A Novel Ferroptosis-Associated Gene Signature to Predict Prognosis in Patients with Uveal Melanoma. Diagnostics (Basel) 2021;11:219. [PMID: 33540700 DOI: 10.3390/diagnostics11020219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
13 Sadybekov AA, Brouillette RL, Marin E, Sadybekov AV, Luginina A, Gusach A, Mishin A, Besserer-Offroy É, Longpré JM, Borshchevskiy V, Cherezov V, Sarret P, Katritch V. Structure-Based Virtual Screening of Ultra-Large Library Yields Potent Antagonists for a Lipid GPCR. Biomolecules 2020;10:E1634. [PMID: 33287369 DOI: 10.3390/biom10121634] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Slater K, Heeran AB, Garcia-Mulero S, Kalirai H, Sanz-Pamplona R, Rahman A, Al-Attar N, Helmi M, O'Connell F, Bosch R, Portela A, Villanueva A, Gallagher WM, Jensen LD, Piulats JM, Coupland SE, O'Sullivan J, Kennedy BN. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. Cancers (Basel) 2020;12:E2950. [PMID: 33066024 DOI: 10.3390/cancers12102950] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Nell RJ, Menger NV, Versluis M, Luyten GP, Verdijk RM, Madigan MC, Jager MJ, van der Velden PA. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.. [DOI: 10.1101/2020.09.16.20191791] [Reference Citation Analysis]
16 Slater K, Heeran AB, Sanz-pamplona R, Kalirai H, Rahman A, Helmi M, Garcia-mulero S, O’connell F, Bosch R, Portela A, Villanueva A, Piulats JM, Gallagher WM, Jensen LD, Coupland SE, O’sullivan J, Kennedy BN. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells.. [DOI: 10.1101/2020.08.23.261545] [Reference Citation Analysis]
17 Khan S, Carvajal RD. Novel Approaches to the Systemic Management of Uveal Melanoma. Curr Oncol Rep. 2020;22:104. [PMID: 32725406 DOI: 10.1007/s11912-020-00965-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
18 Li YZ, Huang Y, Deng XY, Tu CS. Identification of an immune-related signature for the prognosis of uveal melanoma. Int J Ophthalmol 2020;13:458-65. [PMID: 32309184 DOI: 10.18240/ijo.2020.03.14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
19 Croce M, Ferrini S, Pfeffer U, Gangemi R. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. Cancers (Basel) 2019;11:E846. [PMID: 31216772 DOI: 10.3390/cancers11060846] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]